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To examine cross-sectional eﬀects of cognitive reserve (CR) and brain reserve (BR) on cog-
nition across the spectrum of Alzheimer disease (AD).
Methods
We included 663 AD biomarker–positive participants with dementia (probable AD, n = 462) or
in the predementia stages (preclinical/prodromal AD, n = 201). Education was used as a proxy
of CR and intracranial volume as a proxy of BR. Cognition was assessed across 5 domains
(memory, attention, language, visuospatial, and executive functions). We performed multiple
linear regression models to examine eﬀects of CR and BR on cognitive domain Z scores,
adjusted for cerebral atrophy. Furthermore, we assessed diﬀerences in eﬀects according to
disease stage and across degrees of total reserve using a 4-level variable (high CR/high BR, high
CR/low BR, low CR/high BR, and low CR/low BR).
Results
We found positive, independent eﬀects of both CR and BR across multiple cognitive domains.
Stratiﬁcation for disease stage showed that eﬀects of CR on attention and executive functioning
were greater in predementia than in dementia (β = 0.39 vs β = 0.21 [Welch t = 2.40, p < 0.01]
and β = 0.46 vs β = 0.26 [t = 2.83, p < 0.01]). Furthermore, we found a linear trend for better
cognitive performance in all domains in the high CR/high BR group, followed by high CR/low
BR, low CR/high BR, and then low CR/low BR (p for trend <0.05).
Conclusions
CR and BR both independently mitigate cognitive symptoms in AD. The positive eﬀect of CR is
most strongly expressed in the predementia stages and the additive eﬀects of high CR and BR
are most beneﬁcial.
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Glossary
Aβ = β-amyloid; AD = Alzheimer disease; BR = brain reserve; CR = cognitive reserve; ICV = intracranial volume;MCI = mild
cognitive impairment; MMSE = Mini-Mental State Examination; NIA-AA = National Institute on Aging and Alzheimer’s
Association; SCD = subjective cognitive decline.
Neuropathologic and biomarker studies in patients with Alz-
heimer disease (AD) have revealed remarkable interindividual
diﬀerences in the level of cognitive function at a comparable
neuropathologic burden.1–3 To account for these clinicopath-
ologic discrepancies, the concept of reserve has been
proposed.4–6 Reserve describes the capacity to preserve cog-
nitive function in the presence of neuropathology and can be
divided into 2 components: cognitive reserve (CR) and brain
reserve (BR).4 CR is thought to act by recruiting alternate
neural networks or utilizing existing networks more eﬃciently
to cope with neuropathologic changes, and is often estimated
using educational attainment.4–6 When matched for clinical
disease severity, patients with AD with higher education have
more advanced levels of neuropathology,7,8 indicating that
individuals with greater CR can tolerate greater neuropatho-
logic burden. BR represents a higher quantity of neural
resources acting as a buﬀer that enables the brain to better
tolerate emerging neuropathology, and is typically operation-
alized by intracranial volume (ICV) in human neuroimaging
studies.9–11 ICV increases during development12 but remains
largely stable with neurodegeneration due to chronologic aging
or AD,13 and has been shown to act as a resilience factor against
clinical deterioration in the presence of AD pathology.9–11 In
the present study of AD biomarker–positive (preclinical, pro-
dromal, and dementia) participants, we examine the in-
dependent and additive eﬀects of CR and BR on memory,
attention, visuospatial, language, and executive functions, while




In this cross-sectional study, we included 663 participants with
positive AD biomarkers. The sample was selected from the
Amsterdam Dementia Cohort14 and consisted of patients who
visited the memory clinic of the VU University Medical Center
in Amsterdam between January 2008 and December 2015 who
consented to have their data used for research. All participants
underwent standardized dementia screening including medical
history, informant-based history, physical and neurologic
examinations, lumbar puncture, brain MRI, and neuro-
psychological testing. Clinical diagnosis of probable AD or mild
cognitive impairment (MCI) due to AD was established by
consensus in a multidisciplinary team according to National
Institute on Aging and Alzheimer’s Association (NIA-AA)
criteria.15,16 A diagnosis of subjective cognitive decline (SCD)
was established when a patient presented with cognitive com-
plaints in the absence of objective cognitive, neurologic, or
psychiatric impairment.17 Due to positive AD biomarkers and
according to NIA-AA nomenclature,18 these participants were
classiﬁed as preclinical AD. Participants were included based on
(1) diagnosis of probable AD,15 MCI due to AD,16 or SCD17;
(2) positive CSF biomarkers for AD (i.e., β-amyloid [Aβ]42
<638 ng/L or tau/Aβ42 fraction >0.52
19) or a positive
Aβ (18F-ﬂutemetamol, 18F-ﬂorbetaben, 18F-ﬂorbetapir, or
[11C] Pittsburgh compound B) PET scan by visual assess-
ment20; (3) availability of a 3T T1-weighted structural MRI
scan; and (4) Mini-Mental State Examination (MMSE) ≥10.
Exclusion criteria were (1) signiﬁcant cerebrovascular disease
on MRI, (2) a history of substance abuse, (3) major traumatic
brain injury, (4) major psychiatric or neurologic disorders
(other than AD), and (5) meeting core clinical criteria for an
atypical variant of AD (e.g., posterior cortical atrophy; ﬁgure 1).
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained from all participants and the
medical ethics review committee of the VU University Med-
ical Center approved the study.
Figure 1 Flowchart of the sample selection
AD = Alzheimer disease.
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MRI
All participants underwent MRI scans on a 3T MRI
scanner, according to standardized acquisition protocols
including a T1 sequence. Three diﬀerent scanner types
were used: SignaHDxt 3T (n = 493, GE Healthcare
[Cleveland, OH], voxel size 0.94 × 0.94 × 1 mm, echo time
3 milliseconds, repetition time 7.8 milliseconds, ﬂip angle
12°, ﬁeld of view 240 mm), Vantage Titan 3T (n = 105,
Toshiba Medical Systems [Glen Mills, PA], voxel size 1 × 1
× 1 mm, echo time 3.2 milliseconds, repetition time 9.5
milliseconds, ﬂip angle 7°, ﬁeld of view 256 mm), or In-
genuity TF PET-MRI 3T (n = 65, Philips Medical Systems
[Best, the Netherlands], voxel size 0.87 × 0.87 × 1 mm,
echo time 3 milliseconds, repetition time 7 milliseconds,
ﬂip angle 12°, ﬁeld of view 250 mm). All statistical models
included scanner type as a covariate.
CR and BR
As a proxy of CR, we used the Verhage system21 to measure
education. This is a standardized index (range 1–7), with
a score of 1 indicating that primary school was not completed,
while a score of 7 corresponds to an academic degree. ICV was
used as a proxymeasure of BR and was obtained by segmenting
T1-weighted MRI using Statistical Parametric Mapping 12
software (SPM12; Wellcome Trust Centre for Neuroimaging,
Institute of Neurology at University College, London, UK).
This yields volumetric measures of gray matter, white matter,
and CSF, which were summed to provide ICV.
Neurodegeneration
The concepts of CR and BR posit to explain discrepancies
between observed and expected performance based on the
level of underlying neuropathology. Therefore, operationali-
zations of CR and BR should include a measure of neuropa-
thology.22 In the present study, we used whole brain gray
matter volume relative to ICV (reﬂecting cerebral atrophy) as
a surrogate measure of neuropathology.
Cognition
A standardized neuropsychological test battery was used to
assess performance in 5 cognitive domains: memory (visual
association test; Rey Auditory Verbal Learning Test imme-
diate and delayed recall), attention (digit span forward; Trail-
Making Test part A; Stroop test form I and II), executive
functioning (frontal assessment battery; Stroop test form III;
digit span backward), language (category ﬂuency [animal
naming]; naming condition of the visual association test), and
visuospatial ability (number location; dot counting; frag-
mented letters).23,24 To obtain cognitive domain scores, all
raw test scores were ﬁrst converted into Z scores using the
mean and SD of equivalent neuropsychological test scores
from an independent reference group of healthy controls (n =
533, age = 59.7 ± 9.8 years, 46% male, MMSE = 28.9 ± 1.0) of
AD biomarker–negative participants with SCD. Z scores for
Trail-Making Test and Stroop test were inverted as higher
scores indicate worse performance. Z scores were combined
into cognitive domain scores by averaging scores across tests
within each domain. Composite scores for each cognitive
domain were only calculated if there were data available on ≥2
tests within that speciﬁc domain; otherwise that domain score
was classiﬁed as missing (n for missing domain scores:
memory = 7, attention = 7, executive functioning = 10, lan-
guage = 25, visuospatial ability = 26). In addition, MMSE
scores (available for all participants) were used as an index of
global cognitive functioning.
Statistical analysis
We used multiple linear regression models, adjusted for cerebral
atrophy, age, sex, and scanner type, to examine the eﬀects of
education and ICVon cognition. Cognitive domainZ scores and
MMSE scores were the dependent variables in the models and
cases with missing cognitive domain scores were excluded from
the analyses. First, we assessed the predictive eﬀects of education
and ICV separately (model 1), followed by a model including
both predictors (model 2) to examine their independent eﬀects.
Next, we examined whether the eﬀects of education and ICV on
cognition diﬀered according to disease stage, by performing
regression models in predementia participants (SCD or MCI, n
= 201) and in participants with dementia (probable AD, n =
462).Diﬀerences in eﬀects across disease stageswere assessed by
Welch t tests,25 using the regression slopes (β) and corre-
sponding standard error.26,27 To test the assumptions of the
regression analyses, we plotted and checked residuals of all
models. Residuals were normally distributed, heteroscedasticity
was in conformance with test assumptions, and Durbin-Watson
test statistics indicated independence of observations. Further-
more, variance inﬂation factor values, tolerance values, and
correlations between variables did not indicate multicollinearity
between predictors. Next, we dichotomized the total sample
according to low vs high CR using a median split for education
(Verhage 1–5 = low education, 6–7 = high education) and
according to low vs high BR using a mean split for ICV
(1.12–1.51 = low ICV, 1.52–2.01 = high ICV). Using these
dichotomized groups, we computed a 4-level variable repre-
senting degree of total reserve; low CR and BR (CR−/BR−, n =
220), low CR and high BR (CR−/BR+, n = 180), high CR and
low BR (CR+/BR−, n = 121), high CR and BR (CR+/BR+, n =
142). To assess diﬀerences in cognition across these 4 levels, we
ﬁtted general linear models, adjusted for cerebral atrophy, age,
sex, and scanner type, and examined post hoc linear trends
across levels. All statistical analyses were performed in SPSS
version 20 (released 2011, IBM SPSS Statistics for Windows,
Armonk, NY) and statistical signiﬁcance in all models was set at
α = 0.05 (2-tailed), uncorrected for multiple comparisons.
GraphPad Prism (GraphPad Software, La Jolla, CA) version 6.0
was used for the ﬁgures.
Results
Demographic and clinical characteristics of the total sample
and according to disease stage are presented in table 1. There
were no diﬀerences according to disease stage in sex
(p = 0.17), age (p = 0.41), or ICV (p = 0.18), while education
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was lower in participants with dementia than in predementia
participants (p < 0.05). As expected, participants with de-
mentia had lower cognitive scores (p < 0.05) and reduced
ICV-corrected gray matter volumes (i.e., more cerebral atro-
phy, p < 0.05) compared to predementia participants. Pearson
correlation analysis revealed a modest association between
education and ICV in the total sample (r = 0.17, p < 0.01).
Furthermore, ICV-corrected gray matter volume was
moderately associated with cognition (memory: r = 0.31,
attention: r = 0.36, executive functioning: r = 0.41, language:
r = 0.31, visuospatial ability: r = 0.39, and MMSE: r = 0.45, all
p < 0.01), adjusted for age, sex, and scanner type.
Effects of CR and BR on cognition
Multiple regression analyses with adjustment for cerebral at-
rophy, age, sex, and scanner type (model 1) revealed positive
eﬀects of both education and ICV on all cognitive domains
(all p < 0.05; table 2). When combining education and ICV in
a single model (model 2), all eﬀects survived, except for the
eﬀect of ICV on language (p = 0.11; table 2). These results
indicate that, while controlling for the degree of cerebral at-
rophy, both CR and BR have a positive eﬀect on cognition in
participants with positive AD biomarkers.
Effects of CR and BR on cognition according to
disease stage
Next, we stratiﬁed the sample according to disease stage (de-
mentia vs predementia) and performed model 1 and 2 in both
patient groups.Model 1 showed positive eﬀects of education on
attention, executive functioning, and MMSE scores in pre-
dementia participants, and on memory, attention, executive
functioning, visuospatial ability, andMMSE in participants with
dementia (all p < 0.05). Furthermore, there were positive
eﬀects of ICV on executive functioning and MMSE in pre-
dementia participants (p < 0.05) and on memory, attention,
executive functioning, visuospatial ability, and MMSE in par-
ticipants with dementia (all p < 0.05; table 2). When combining
education and ICV in one model (model 2), we found that all
eﬀects of education and ICV survived (p < 0.05), with the
exception of the eﬀects on memory in participants with de-
mentia (p = 0.08 for education, p = 0.11 for ICV; table 2) and
the eﬀect of ICV on MMSE in predementia participants (p =
0.07; table 2). The eﬀect sizes of education on attention (β =
0.39, p < 0.01 vs β = 0.21, p < 0.01) and executive functioning
(β = 0.46, p < 0.05 vs β = 0.26, p < 0.01) were 46% and 43%
larger in predementia participants than in participants with
dementia (Welch t = 2.40, p < 0.01 and t = 2.83, p < 0.01;
ﬁgure 2A). This indicates that high CR is especially beneﬁ-
cial for cognition in early stages of AD. There were no dif-
ferences for the eﬀects of ICV (i.e., BR) according to disease
stage (ﬁgure 2B).
Differences in cognitive functioning across
levels of reserve
Subsequently, we constructed a 4-level variable
(i.e., CR−/BR−, CR−/BR+, CR+/BR−, and CR+/BR+) and
ﬁtted general linear models, adjusted for cerebral atrophy, age,
sex, and scanner type, to assess cognitive performance across
Table 1 Demographic and clinical characteristics of the total sample and according to disease stage
Total (n = 663) Predementia (n = 201) Dementia (n = 462)
Diagnosis SCD (70); MCI (131) Probable AD (462)
Sex, % male 49 53 47
Age, y 66.2 (7.4) 66.6 (7.5) 66.1 (7.4)
Education, Verhage, median (range) 5 (2–7) 5 (2–7)a 5 (2–7)
ICV 1.51 (0.16) 1.52 (0.16) 1.50 (0.16)
MMSE 22.7 (4.8) 27.0 (2.2)a 20.8 (4.3)
Cerebral atrophyb 0.39 (0.04) 0.41 (0.04)a 0.38 (0.04)
Cognitive function Z scoresc
Memory −3.78 (3.27) −1.39 (1.56)a −4.83 (3.36)
Attention −1.87 (2.58) −0.39 (0.81)a −2.53 (2.81)
Executive functioning −1.84 (1.81) −0.50 (0.91)a −2.43 (1.80)
Language −1.09 (1.33) −0.29 (0.58)a −1.45 (1.41)
Visuospatial ability −1.69 (2.67) −0.21 (0.87)a −2.35 (2.93)
Abbreviations: AD = Alzheimer disease; ICV = intracranial volume in dm3; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; SCD =
subjective cognitive decline.
Values are depicted asmean (SD) unless otherwise indicated. Group comparisonswere performed using χ2,Mann-WhitneyU, or independent samples t tests,
where appropriate.
a Predementia > dementia.
b Gray matter volumes relative to ICV; lower values indicate more cerebral atrophy.
c Z scores calculated using the mean and SD of independent reference group.
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levels. We observed a linear trend across all cognitive
domains and MMSE with highest estimated marginal means
for CR+/BR+, followed by CR+/BR−, CR−/BR+, and then
CR−/BR− (p for trend <0.05, ﬁgure 3). Sensitivity analysis
(switching the CR−/BR+ and CR+/BR− groups) conﬁrmed
the linear trend (p < 0.05).
Discussion
The main ﬁndings of our study are (1) CR and BR both have
independent positive eﬀects on cognition in participants with
biomarker evidence of AD, adjusted for cerebral atrophy, (2)
the eﬀects of CR on attention and executive functioning were
greater in predementia participants than in participants with
dementia, (3) the eﬀects of CR were generally greater than
those of BR, and (4) there was a linear trend for better cog-
nitive performance in all domains (adjusted for cerebral at-
rophy) in the CR+/BR+ group, followed by CR+/BR−,
CR−/BR+, and then CR−/BR−.
The positive eﬀects of CR and BR (as indicated by education
and ICV) on cognitive functioning in this study are in line
with most literature, suggesting that higher education and
greater ICV positively inﬂuence the cognitive trajectory of
patients with AD.7–11 We extend on these ﬁndings by
demonstrating that CR and BR diﬀerentially mitigate cogni-
tive symptoms in AD, as CR was most beneﬁcial in pre-
dementia stages (there was no disease stage–speciﬁc eﬀect for
BR) and the eﬀects of CR were overall stronger than those of
BR. Although CR and BR are related to similar underlying
factors, our results thus indicate that they are at least partially
separate components of a larger concept (i.e., reserve) rather
than interchangeable terms describing a single entity. This is
further highlighted by the small correlation (r = 0.17) be-
tween education and ICV in our sample.
Physiologic mechanisms underlying the protective eﬀect of
CR may include facilitating the development of new cognitive
strategies,4 modulation of functional connectivity in hub
regions such as the posterior cingulate cortex,28,29 and
strengthened network reliability,30 which are all associated
with higher education. These mechanisms actively support
the brain to cope with neuropathology. The mechanism un-
derlying BR is to increase resilience to neuropathology
through greater quantities of premorbid brain parenchyma. In
the event of neurodegeneration, the necessary structural in-
tegrity to maintain normal cognitive functioning will be
retained for a longer period in individuals with high BR than in
individuals with low BR.4–6 More detailed examinations into
Table 2 Effects of education and intracranial volume (ICV) in the total sample and according to disease stage
Domain
Education ICV
Model 1a Model 2b Model 1a Model 2c
Memory 0.12d 0.10d 0.18d 0.16d
Attention 0.24d 0.22d 0.21d 0.15d
Executive function 0.31d 0.28d 0.26d 0.19d
Language 0.11d 0.10d 0.11d 0.08
Visuospatial ability 0.16d 0.14d 0.18d 0.15d
MMSE 0.28d 0.25d 0.26d 0.19d
Domain
Education ICV
Predementia (n = 201) Dementia (n = 462) Predementia (n = 201) Dementia (n = 462)
Model 1a Model 2b Model 1a Model 2b Model 1a Model 2c Model 1a Model 2c
Memory 0.04 0.02 0.10d 0.08 0.12 0.12 0.13d 0.10
Attention 0.40d 0.39d 0.23d 0.21d 0.12 0.06 0.21d 0.14d
Executive function 0.48d 0.46d 0.28d 0.26d 0.26d 0.18d 0.23d 0.15d
Language 0.13 0.13 0.06 0.06 −0.01 −0.03 0.08 0.05
Visuospatial ability 0.10 0.08 0.16d 0.14d 0.15 0.14 0.17d 0.13d
MMSE 0.34d 0.32d 0.27d 0.25d 0.21d 0.16 0.23d 0.15d
Abbreviations: ICV = intracranial volume; MMSE = Mini-Mental State Examination.
Values depicted are partial regression coefficients (β).
a Effects adjusted for cerebral atrophy, age, sex, and scanner type.
b Effects adjusted for cerebral atrophy, age, sex, scanner type, and intracranial volume.
c Effects adjusted for cerebral atrophy, age, sex, scanner type, and education.
d Significant effect at p < 0.05.
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the eﬀects of BR, for instance focused on microstructural
integrity of the brain (e.g., synaptic density measured with
PET31), could provide a more comprehensive depiction of the
mechanisms behind the protective eﬀect of BR in AD.
A considerable body of literature has described positive eﬀects
of education and ICV on cognition, but these eﬀects—
especially for ICV—have not been replicated in all studies.32,33
Strengths of the present study, such as the large sample size,
inclusion of AD biomarker–positive participants ranging from
preclinical to dementia stages, availability of 3TMRI, SPM12-
based tissue segmentation,34 and detailed neuropsychological
testing, likely increased sensitivity for detecting eﬀects of
education and ICV compared to some previous studies. Some
limitations of the present study also need to be addressed.
First, there are inherent limitations related to cross-sectional
designs and longitudinal follow-up studies are needed to
conﬁrm whether reserve has a direct eﬀect on the progression
of cognitive decline. Second, the diﬀerence in sample size
between the predementia group (n = 201) and dementia
group (n = 462) may have resulted in more signiﬁcant eﬀects
being observed in the dementia group with similar eﬀect sizes.
However, power analyses revealed that both sample sizes were
suﬃcient to detect eﬀects and interpretation of results was
focused on (diﬀerences in) eﬀect sizes rather than levels of
signiﬁcance. Possible associations between predictors, espe-
cially between ICV and cerebral atrophy, may have resulted in
multicollinearity in the regression models. However, we
conducted thorough assessment of multicollinearity by ex-
amining tolerance values and variance inﬂation factors, and
these assessments revealed no indication for signiﬁcant mul-
ticollinearity in the regression models. Furthermore, the
modest correlations between predictors (r = 0.32 between
ICV and cerebral atrophy in the total sample) fall well below
the assumption that a correlation higher than r = 0.70 indi-
cates multicollinearity.35 Third, our relatively young cohort
(mean age 66.2 ± 7.4 years) may be characterized by an
overrepresentation of hippocampal-sparing AD36 and relative
paucity of comorbidities. This should be taken into account
when generalizing or replicating our ﬁndings to cohorts with
a higher average age. Finally, reserve is a hypothetical con-
struct that is often measured using proxies, which come with
inherent limitations and imperfections. For instance, there
may be geographical diﬀerences related to access and level of
education and there exists a range of methods to measure
education, from total years of school to categorical scales such
Figure 2 Effect sizes of education and intracranial volume
(ICV) on cognition according to disease stage
(A) Effect size of education. (B) Effect size of ICV. Effect sizes are partial
regression coefficients (β), adjusted for cerebral atrophy, age, sex,
and scanner type. Error bars indicate the standard error. *Significant effect
at p < 0.05. **Difference of effect sizes between groups (Welch t test,
p < 0.05). MMSE = Mini-Mental State Examination.
Figure 3 Standardized cognitive domain and Mini-Mental
State Examination (MMSE) scores (adjusted for
cerebral atrophy) across degrees of total reserve
Data are estimated marginal means (EMM) (plus standard error) for cogni-
tive domain Z scores, adjusted for cerebral atrophy, age, sex, and scanner
type. BR = brain reserve; CR = cognitive reserve. *p for trend <0.05. **p for
trend <0.01. #MMSE scores were converted to Z scores for visualization
purposes; we used raw scores in the statistical analyses.
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as the Verhage scale.21 Also, education is associated with other
socioeconomic characteristics (e.g., occupation, access to
general health care), which in turn may aﬀect CR. Further-
more, ICV serves as an easily obtainable proxy of BR but may
reﬂect early childhood brain development to a higher extent
than later childhood and adolescent inﬂuences.
Our results indicate that CR, as measured by education, has
the greatest potential to delay or slow down cognitive decline
in AD. This highlights the importance of education in early
life. However, our ﬁndings regarding the diﬀerential eﬀects of
CR between disease stages may also serve tailoring clinical
interventions in late life. We have shown that the eﬀects of
CR are especially beneﬁcial in the earlier phases of the disease,
which indicates that interventions (e.g., physical activity
interventions37 or cognitive training) would preferentially be
oﬀered early on in the disease course. BR as measured by ICV
is in itself a nonmodiﬁable factor. However, our results re-
garding the additive eﬀects of CR and BR suggest that inter-
ventions tailored to increasing CR would show maximized
treatment eﬀects in individuals with high BR. These insights
may help to tailor interventions and to reduce the rate of
cognitive decline in neurodegenerative diseases and promote
successful aging.
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What are the cross-sectional eﬀects of cognitive reserve (CR)
and brain reserve (BR) on cognition across the spectrum of
Alzheimer disease (AD)?
Summary answer
CR and BR both independently and additively mitigate cog-
nitive symptom severities in AD, with the beneﬁts of CR being
strongest in predementia stages.
What is known and what this article adds
CR and BR both mitigate the cognitive symptoms of AD by
helping patients cope with neuropathologic changes. This
study elucidates how CR and BR independently and addi-
tively aﬀect various cognitive domains in diﬀerent AD stages.
Participants and setting
The study included 462 persons with dementia-stage AD and
201 persons with predementia AD. They were selected from
the Amsterdam Dementia Cohort and had visited the VU
University Medical Center Amsterdam between January 2008
and December 2015.
Design, size, and duration
The study used education levels, as measured with the
Verhage system, as a proxy for CR and intracranial volume
(ICV), as measured with MRI, as a proxy for BR. The ratio of
whole-brain gray matter volume to ICV was used as a proxy
for cerebral atrophy.
Primary outcomes
The primary outcomes were scores in 5 cognition domains:
memory, attention, visuospatial, language, and executive
functions.
Main results and the role of chance
Compared to patients in predementia stages, those with de-
mentia had lower education, lower cognitive scores, and greater
cerebral atrophy (p < 0.05 for all). Multiple regression analyses
showed that, controlling for the eﬀects of cerebral atrophy,
greater education and ICV had independent positive eﬀects on
all cognitive domains except for the absence of an eﬀect of ICV
on language (p < 0.05). General linear models conﬁrmed the
additively beneﬁcial eﬀects of education and ICV on all
domains (p < 0.05 for trend). Analyses by disease stage showed
that the eﬀects of CR were especially beneﬁcial in predementia
cases and were generally larger than the eﬀects of BR, but there
was no beneﬁt for education in patients with dementia.
Bias, confounding, and other reasons
for caution
The cross-sectional design of this study precluded any de-
termination of whether CR and BR directly aﬀect the progression
of cognitive decline. CR and BR were measured via proxies.
Generalizability to other populations
The participants were relatively young (mean age 66.2 ± 7.4
years), so there is limited generalization to older patients.
Study funding/potential competing interests
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